Alnylam Pharmaceuticals
ALNY
626 hedge funds and large institutions have $34.8B invested in Alnylam Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 106 funds opening new positions, 237 increasing their positions, 205 reducing their positions, and 67 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 4 → 10 (+6)
58% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 67
16% more capital invested
Capital invested by funds: $30.1B → $34.8B (+$4.78B)
16% more repeat investments, than reductions
Existing positions increased: 237 | Existing positions reduced: 205
15% more call options, than puts
Call options by funds: $274M | Put options by funds: $238M
6% more funds holding
Funds holding: 593 → 626 (+33)
0.45% more ownership
Funds ownership: 99.08% → 99.53% (+0.45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$469M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$166M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$112M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$91.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$408M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$334M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$98.3M |
| 4 |
BlackRock
New York
|
-$83.7M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$82.3M |
ALNY Hedge Fund Activity: Q1 2025 in Review
626 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2025, worth a combined $34.8B — up 16% from $30.1B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new ALNY positions and 67 closed out — a net gain of 39 holders — while 237 added to existing stakes and 205 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $469M. The largest seller was Wellington Management Group, cutting an estimated $408M.
- 626 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2025, up from 593 in Q4 2024.
- Funds reported $34.8B of Alnylam Pharmaceuticals stock for Q1 2025, up 16% quarter-over-quarter.
- 106 funds opened new Alnylam Pharmaceuticals positions in Q1 2025 and 67 closed out, a net change of +39 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2025 was Fidelity Investments, an estimated $469M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2025 was Wellington Management Group, an estimated $408M sold.
Based on aggregated 13F filings for Q1 2025.